Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab's efficacy in vitro?
T Hurrell, K Outhoff - OncoTargets and therapy, 2013 - Taylor & Francis
Introduction Despite trastuzumab having enhanced selectivity for human epidermal growth
factor receptor 2 (HER-2) overexpressing breast cancer cells, treatment is hampered by …
factor receptor 2 (HER-2) overexpressing breast cancer cells, treatment is hampered by …
[PDF][PDF] Pixelenkénti autofluoreszcencia korrigált FRET mérés és implementálása Pannoramic Confocal konfokális patológiai szkennerre
R István - dea.lib.unideb.hu
FITC fluoreszcein-izotiocianát FRET Förster Rezonancia Energiatranszfer FWHM Full width
at half maximum GBM Glioblasztóma multiforme HEPES 4-(2-hidroxietil)-1 …
at half maximum GBM Glioblasztóma multiforme HEPES 4-(2-hidroxietil)-1 …
[HTML][HTML] HER2 Expression Changes in Breast Cancer Xenografts Following Therapeutic Intervention Can Be Quantified Using PET Imaging and 18F-Labelled Affibody …
G Kramer-Marek, DO Kiesewetter… - Journal of nuclear …, 2009 - ncbi.nlm.nih.gov
Methods To assess the correlation of signal observed by PET with receptor expression, the
tracer was administered to athymic nude mice bearing subcutaneous human breast cancer …
tracer was administered to athymic nude mice bearing subcutaneous human breast cancer …
[HTML][HTML] Scientific memory from the early nineties; a common project with professors late János Gergely and Anna Erdei
A Falus, Z Bajtay - Biologia Futura, 2021 - Springer
Based on the findings of common project 29 years ago, the Scandinavian J. of Immunology
accepted and published our paper entitled by “FcγR-Dependent Regulation of the …
accepted and published our paper entitled by “FcγR-Dependent Regulation of the …
Conjugates comprising an anti-EGFR1 antibody
A Leppanen, FS Ekholm, J Helin, H Salo… - US Patent …, 2020 - Google Patents
The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an
EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran …
EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran …
[PDF][PDF] DEBRECEN, 2013
FÁ István - dea.lib.unideb.hu
The theoretical background of resonance energy transfer was published in 1948 by Förster
(1) who described the non-radiative short distance transfer of energy from an excited donor …
(1) who described the non-radiative short distance transfer of energy from an excited donor …
[PDF][PDF] Terapeutické monoklonální protilátky v léčbě a ve vývoji
O Farsa - Chemické listy, 2013 - chemicke-listy.cz
465 dorů, proto byla angiogeneze navržena jako cíl zásahu protinádorové terapie již v 70.
letech. ReceptorVEGFR-2 je selektivně exprimován na nádorových endoteliálních buňkách …
letech. ReceptorVEGFR-2 je selektivně exprimován na nádorových endoteliálních buňkách …
[PDF][PDF] Trends in Peptide and Protein Sciences
A Haeri, M Osouli - 2020 - academia.edu
Conventional cancer management is directly associated with many problems, including
accurate therapeutic delivery to tumours and serious side effects of chemotherapeutics. A …
accurate therapeutic delivery to tumours and serious side effects of chemotherapeutics. A …
[PDF][PDF] HER2 pozitív tumorok kombinált antitest terápiája
T Gábor - dea.lib.unideb.hu
DMEM Dulbecco's Modified Eagle Medium EC50 50%-os aktivitáshoz szükséges
koncentráció EGFR epidermális növekedési faktor receptor (HER1, EGFR) ELISA enzimhez …
koncentráció EGFR epidermális növekedési faktor receptor (HER1, EGFR) ELISA enzimhez …
Conjugates comprising an anti-EGFR1 antibody
A Leppanen, FS Ekholm, J Helin, H Salo… - US Patent …, 2019 - Google Patents
The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an
EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran …
EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran …